Preview Mode Links will not work in preview mode

Aug 20, 2019

Chronic Lymphocytic Leukemia Update, Issue 1, 2019 — Part 2: Our most recent one-on-one interview with Dr Mato featuring emerging research and cases from his practice:

  • Emerging data and recent advances in the management of CLL (00:00)
  • Perspective on the role of MRD assessment in therapeutic decision-making (03:13)
  • Duration of therapy for patients with CLL; integration of venetoclax into the treatment algorithm (05:44)
  • Available data with the addition of rituximab or obinutuzumab to novel therapies (08:07)
  • Selection of patients with CLL for treatment with FCR (fludarabine/cyclophosphamide/rituximab) (11:44)
  • Novel combination approaches to limiting the duration of therapy for patients with CLL (13:36)
  • Spectrum and incidence of toxicities with ibrutinib/venetoclax compared to either agent alone (15:41)
  • Therapeutic options for patients with CLL in the first-line setting (17:55)
  • Safety profile and quality of life with venetoclax versus ibrutinib (19:37)
  • Frequency of and reasons for discontinuation of therapy with ibrutinib (22:37)
  • Left atrial abnormality as a predictor of ibrutinib-associated atrial fibrillation in patients with CLL (24:48)
  • Real-world outcomes and management strategies for patients with venetoclax-treated CLL in the United States (27:04)
  • Experience conducting real-world outcome studies (29:06)
  • Role of chemoimmunotherapy in the management of relapsed/refractory CLL (31:24)
  • Clinical experience with and management of ibrutinib-associated adverse events (33:21)
  • Investigation of ibrutinib in combination with CAR T-cell therapy for CLL (37:37)
  • Case: A woman in her mid-70s with del(17p) CLL and no IGHV mutation experiences arthralgia and hypertension during second-line therapy with ibrutinib (40:53)
  • Incidence and management of hypertension associated with ibrutinib (42:52)
  • Dose reductions of ibrutinib to mitigate side effects; effect on efficacy (46:21)
  • Case: A man in his mid-60s with a history of hypertension and atrial fibrillation receives acalabrutinib as first-line therapy for CLL (49:08)
  • Headaches and hypertension associated with acalabrutinib (50:20)
  • Comparative efficacy and spectrum of kinase activity with ibrutinib, acalabrutinib and zanubrutinib (52:38)
  • Activity and tolerability of acalabrutinib versus ibrutinib (54:38)
  • Case: A woman in her mid-50s with von Willebrand disease and CLL receives venetoclax after experiencing disease progression through several lines of therapy (56:58)
  • Dose adjustments of venetoclax and management of TLS (1:01:18)
  • Case: A woman in her late 80s with del(13q) CLL with IGHV mutation, symptomatic anemia and lymphadenopathy receives first-line obinutuzumab (1:04:19)
  • Clinical experience with obinutuzumab-associated infusion-related reactions (1:06:26)
  • Choice of first-line therapy for older patients with CLL (1:08:34)

CME information and select publications